Varicella Zoster- Hyperimmune globulin

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D.
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID
Varicella Zoster- Hyperimmune globulin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • VZV post-exposure prophylaxis in high-risk individuals:
    • Immunocompromised children and adults
    • Newborns of mothers with varicella around the time of delivery
    • Premature infants
    • Infants < 1 year of age
    • Adults without evidence of the immunity
    • Pregnant women
  • ACIP and AAP recommend administration of VariZIG as soon as possible after exposure and within 10 days[1]
    • The ACIP and AAP recommendations for post-exposure prophylaxis:
      • Immunocompromised patients without evidence of immunity.
      • Newborn infants whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after delivery).
      • Hospitalized premature infants born at ≥ 28 weeks of gestation whose mothers do not have evidence of immunity to varicella.
      • Hospitalized premature infants born at < 28 weeks of gestation or who weigh ≤1000 g at birth, regardless of their mother’s evidence of immunity to varicella.
      • Pregnant women without evidence of immunity.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: March 7, 2019